• Update on Advanced Anti-CD20 Therapeutics to Improve Outcomes for Patients with Multiple Sclerosis

    Saturday, September 21st, 2024 from 7:30am – 8:30am EDT

  • 1. All of the following prescreening labs are needed prior to start an anti-CD20 monoclonal antibody EXCEPT:*
  • 2. In the Ultimate I/II studies of ublituximab, which of the following is FALSE?*
  • 3. Your next clinic patient is a 35-year-old man who presents with a new diagnosis of multiple sclerosis. He is concerned about his increased risk for disability in the future and has researched different treatments options online but is unsure of which one to choose. With all other conditions and factors being equal, along without consideration of side effects, which of the following are considered to be high efficacy medications?*
  • 4. What is TRUE about an anti-CD 20 therapeutic’s impact on peripheral B-cells?*

  • Overall Activity Feedback

  • Please rate the extent to which this activity met the following objectives:
    Rows
  • Please provide us with feedback regarding your experience at the activity:
    Rows
  • Please rate the faculty on their overall teaching ability:
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Should be Empty: